参考文献/References:
[1]梁小婷.干细胞治疗心力衰竭临床研究进展[J].心血管病学进展,2018, 39(3) :379-384.
[2] Mummery CL. Perspectives on the use of human induced pluripotent stem cell-derived cardiomyocytes in biomedical research[J]. Stem Cell Reports, 2018,11(6):1306-1311.
[3] Blau HM, Daley GQ. Stem cells in the treatment of disease[J]. N Engl J Med, 2019,380(18):1748-1760.
[4] Yoshida Y, Yamanaka S. Induced pluripotent stem cells 10 years later: for cardiac applications[J]. Circ Res, 2017,120(12):1958-1968.
[5] Lian X, Zhang J, Azarin SM, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/βeta-catenin signaling under fully defined conditions[J]. Nat Protoc,2013,8(1):162-175.
[6] Mummery CL, Zhang J, Ng ES, et al. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview[J]. Circ Res, 2012,111(3):344-58.
[7] Lian X, Hsiao C, Wilson G, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling[J]. Proc Natl Acad Sci U S A,2012,109(27):E1848- E1857.
[8] Rowe RG, Daley GQ. Induced pluripotent stem cells in disease modelling and drug discovery[J]. Nat Rev Genet,2019,20(7):377-388.
[9] Sharma A, McKeithan WL, Serrano R, et al. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity[J]. Nat Protoc, 2018,13(12):3018-3041.
[10] Ross SB, Fraser ST, Semsarian C. Induced pluripotent stem cell technology and inherited arrhythmia syndromes[J]. Heart Rhythm,2018,15(1):137-144.
[11] Liu C, Oikonomopoulos A, Sayed N, et al. Modeling human diseases with induced pluripotent stem cells:from 2D to 3D and beyond[J]. Development, 2018,145(5):dev156166.
[12] Nugraha B, Buono MF, von Boehmer L, et al. Human cardiac organoids for disease modeling[J]. Clin Pharmacol Ther, 2019,105(1):79-85.
[13] Soldner F, Jaenisch R. Stem cells, genome editing, and the path to translational medicine[J]. Cell,2018,175(3):615-632.
[14] Protze SI, Liu J, Nussinovitch U, et al. Sinoatrial node cardiomyocytes derived from human pluripotent cells function as a biological pacemaker[J]. Nat Biotechnol, 2017,35(1):56-68.
[15] Lee JH, Protze SI, Laksman Z, et al. Human pluripotent stem cell-derived atrial and ventricular cardiomyocytes develop from distinct mesoderm populations[J]. Cell Stem Cell, 2017, 21(2):179-194,e4.
[16] Tu C, Chao BS, Wu JC. Strategies for improving the maturity of human induced pluripotent stem cell-derived cardiomyocytes[J]. Circ Res, 2018,123(5):512-514.
[17] Jiang Y, Park P, Hong SM, et al. Maturation of cardiomyocytes derived from human pluripotent stem cells:current strategies and limitations[J]. Mol Cells, 2018,41(7):613-621.